Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.

Diabetes Care
J Hans DeVriesLiraglutide-Detemir Study Group

Abstract

We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%. In 988 participants from North America and Europe uncontrolled on metformin ± sulfonylurea, sulfonylurea was discontinued and liraglutide 1.8 mg/day added for 12 weeks (run-in). Subsequently, those with A1C ≥7% were randomized 1:1 to 26 weeks' open-label addition of insulin detemir to metformin + liraglutide (n = 162) or continuation without insulin detemir (n = 161). Patients achieving A1C <7% continued unchanged treatment (observational arm). The primary end point was A1C change between randomized groups. Of 821 participants completing the run-in, 61% (n = 498) achieved A1C <7% (mean change -1.3% from 7.7% at start), whereas 39% (n = 323) did not (-0.6% from 8.3% at start). During run-in, 167 of 988 (17%) withdrew; 46% of these due to gastrointestinal adverse events. At week 26, A1C decreased further, by 0.5% (from 7.6% at randomization) with insulin detemir (n = 162) versus 0.02% increase without insulin detemir (n = 157) to 7.1 and 7.5%, respectively (estimated treatment difference -0.52 [95% CI -0.68 to -0.36]; P < 0.0001). Forty-three percent of participants wi...Continue Reading

References

Sep 18, 2007·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Prabhakar ViswanathanParesh Dandona
Sep 25, 2007·The New England Journal of Medicine·Rury R HolmanUNKNOWN 4-T Study Group
May 9, 2008·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Catherine A SheffieldRobert A Hamilton
Aug 19, 2009·Diabetologia·D Russell-JonesUNKNOWN Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group
Oct 24, 2009·The New England Journal of Medicine·Rury R HolmanUNKNOWN 4-T Study Group
Jan 29, 2010·Diabetes Care·UNKNOWN American Diabetes Association
Feb 19, 2010·The New England Journal of Medicine·Mary Parks, Curtis Rosebraugh
Dec 8, 2010·Annals of Internal Medicine·David M Nathan

❮ Previous
Next ❯

Citations

Jun 26, 2013·Advances in Therapy·Anthony H Barnett
May 30, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Ciara M MulliganDarren M McLaughlin
Jun 21, 2013·Current Opinion in Pediatrics·Jamie R Wood, Janet Silverstein
Jun 1, 2012·Diabetes, Obesity & Metabolism·J J Holst, T Vilsbøll
Dec 24, 2013·Drug Design, Development and Therapy·Dominique Xavier BrownMarc Evans
May 3, 2013·Vascular Health and Risk Management·Bo Ahrén
Nov 6, 2012·World Journal of Diabetes·Nikolaos Papanas, Efstratios Maltezos
Oct 2, 2013·Indian Journal of Endocrinology and Metabolism·Ambika Gopalakrishnan UnnikrishnanPaturi V Rao
Sep 4, 2013·International Journal of Obesity : Journal of the International Association for the Study of Obesity·J van CanW H M Saris
Nov 17, 2012·American Journal of Therapeutics·Jeffrey S Freeman, Edward S Horton
Feb 14, 2013·Current Opinion in Endocrinology, Diabetes, and Obesity·Susan L Samson, Alan Garber
Feb 18, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Lisa ElliottTrine Stissing
Jun 24, 2016·Expert Review of Endocrinology & Metabolism·Stephen Cl GoughVincent C Woo
Jun 26, 2012·Expert Opinion on Pharmacotherapy·Eduard Montanya
Aug 18, 2012·Expert Opinion on Biological Therapy·Ram Kela, Melanie J Davies
Oct 11, 2013·Current Medical Research and Opinion·Ronald Goldenberg
Jan 6, 2016·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberUNKNOWN American College of Endocrinology (ACE)
Aug 24, 2013·The American Journal of Medicine·Luigi F Meneghini
Oct 20, 2012·Annales d'endocrinologie·Thomas CunyBertrand Cariou
Dec 8, 2015·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberUNKNOWN American College of Endocrinology (ACE)
Feb 28, 2013·Journal of Clinical Pharmacy and Therapeutics·Susan A Cornell
Mar 2, 2013·Diabetes, Obesity & Metabolism·A J Garber
Oct 24, 2013·Diabetes, Obesity & Metabolism·T R EinarsonM E H Hemels
Jul 7, 2015·European Journal of Pharmacology·Birgitte AndersenBo Ahrén
Nov 26, 2015·Clinical Pharmacokinetics·Lisbeth V JacobsenSteen H Ingwersen
Feb 9, 2016·Journal of Diabetes·Zachary Bloomgarden, Andrew Drexler

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.